ASTRO 2022 | Advances in digital pathology and artificial intelligence for prostate cancer

Osama Mohamed, MD, PhD, University of California, San Francisco, CA, discusses the latest advances in digital pathology and artificial intelligence (AI) for prostate cancer, including the development of prognostic and predictive biomarkers. These advances have enabled the prediction of patients who will most benefit from hormone therapy alongside radiotherapy, and has enabled the determination of the level of risk of recurrence. This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.